Meihua’s planned upgrade of small-volume amino-acid production at Tongliao has reached the beginning of the commissioning window described in its 10 July announcement. The Chinese supplier originally scheduled phased completion and production starts between the fourth quarter of 2026 and the first half of 2027.
The project carries a planned investment of RMB 300–500 million. It combines changes to existing lines with additional products, including planned annual capacities of 8,000 tonnes for glutamine and 3,000 tonnes for proline after upgrading.
The announcement also describes new lines and flexible production arrangements. Those are design plans, rather than evidence that all capacity is now operating or available for immediate export.
Confirm the milestone before booking supply
For food-ingredient buyers, the relevant follow-up is the status of the particular amino acid and grade. Ask whether the line is under construction, in trial production or commercially qualified, and request an achievable sample and delivery timetable.
A plant’s total planned capacity should not be treated as a guaranteed allocation. Flexible lines also need a confirmed production schedule for the specific product being ordered.
Qualification discussions can connect the material specification with the manufacturing site and supporting quality documents. Food and pharmaceutical applications should retain their own requirements rather than sharing an assumed approval. This report revisits the published project timetable; it does not claim a new commissioning confirmation from Meihua.
Beta-alanine crystals photographed under polarised light; not a Meihua product or one of the announced production lines.
Further reading
Researched and written with AI assistance; references are listed for verification.



